228 related articles for article (PubMed ID: 24971483)
41. Requirement of FADD, NEMO, and BAX/BAK for aberrant mitochondrial function in tumor necrosis factor alpha-induced necrosis.
Irrinki KM; Mallilankaraman K; Thapa RJ; Chandramoorthy HC; Smith FJ; Jog NR; Gandhirajan RK; Kelsen SG; Houser SR; May MJ; Balachandran S; Madesh M
Mol Cell Biol; 2011 Sep; 31(18):3745-58. PubMed ID: 21746883
[TBL] [Abstract][Full Text] [Related]
42. Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
Mohs A; Kuttkat N; Reißing J; Zimmermann HW; Sonntag R; Proudfoot A; Youssef SA; de Bruin A; Cubero FJ; Trautwein C
J Hepatol; 2017 Apr; 66(4):743-753. PubMed ID: 28011329
[TBL] [Abstract][Full Text] [Related]
43. The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor?
Seki E; Brenner DA
J Hepatol; 2007 Aug; 47(2):307-9. PubMed ID: 17566588
[TBL] [Abstract][Full Text] [Related]
44. TAK1: Another mesh in the NF-κB - JNK controlled network causing hepatocellular carcinoma.
Greten FR
J Hepatol; 2011 Sep; 55(3):721-723. PubMed ID: 21601601
[TBL] [Abstract][Full Text] [Related]
45. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
Varfolomeev E; Maecker H; Sharp D; Lawrence D; Renz M; Vucic D; Ashkenazi A
J Biol Chem; 2005 Dec; 280(49):40599-608. PubMed ID: 16227629
[TBL] [Abstract][Full Text] [Related]
46. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
47. A lymphotoxin-driven pathway to hepatocellular carcinoma.
Haybaeck J; Zeller N; Wolf MJ; Weber A; Wagner U; Kurrer MO; Bremer J; Iezzi G; Graf R; Clavien PA; Thimme R; Blum H; Nedospasov SA; Zatloukal K; Ramzan M; Ciesek S; Pietschmann T; Marche PN; Karin M; Kopf M; Browning JL; Aguzzi A; Heikenwalder M
Cancer Cell; 2009 Oct; 16(4):295-308. PubMed ID: 19800575
[TBL] [Abstract][Full Text] [Related]
48. Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling.
Sessler T; Healy S; Samali A; Szegezdi E
Pharmacol Ther; 2013 Nov; 140(2):186-99. PubMed ID: 23845861
[TBL] [Abstract][Full Text] [Related]
49. Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure.
Gehrke N; Wörns MA; Mann A; Hövelmeyer N; Waisman A; Straub BK; Galle PR; Schattenberg JM
Cell Death Dis; 2022 May; 13(5):510. PubMed ID: 35641486
[TBL] [Abstract][Full Text] [Related]
50. Novel Phosphorylations of IKKγ/NEMO.
Lee SH; Toth Z; Wong LY; Brulois K; Nguyen J; Lee JY; Zandi E; Jung JU
mBio; 2012 Nov; 3(6):e00411-12. PubMed ID: 23131831
[TBL] [Abstract][Full Text] [Related]
51. NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling.
Legarda-Addison D; Hase H; O'Donnell MA; Ting AT
Cell Death Differ; 2009 Sep; 16(9):1279-88. PubMed ID: 19373245
[TBL] [Abstract][Full Text] [Related]
52. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways.
Schattenberg JM; Schuchmann M; Galle PR
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():213-9. PubMed ID: 21199533
[TBL] [Abstract][Full Text] [Related]
53. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis.
Ikeda F; Deribe YL; Skånland SS; Stieglitz B; Grabbe C; Franz-Wachtel M; van Wijk SJ; Goswami P; Nagy V; Terzic J; Tokunaga F; Androulidaki A; Nakagawa T; Pasparakis M; Iwai K; Sundberg JP; Schaefer L; Rittinger K; Macek B; Dikic I
Nature; 2011 Mar; 471(7340):637-41. PubMed ID: 21455181
[TBL] [Abstract][Full Text] [Related]
54. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
Pikarsky E; Porat RM; Stein I; Abramovitch R; Amit S; Kasem S; Gutkovich-Pyest E; Urieli-Shoval S; Galun E; Ben-Neriah Y
Nature; 2004 Sep; 431(7007):461-6. PubMed ID: 15329734
[TBL] [Abstract][Full Text] [Related]
55. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis.
Dannappel M; Vlantis K; Kumari S; Polykratis A; Kim C; Wachsmuth L; Eftychi C; Lin J; Corona T; Hermance N; Zelic M; Kirsch P; Basic M; Bleich A; Kelliher M; Pasparakis M
Nature; 2014 Sep; 513(7516):90-4. PubMed ID: 25132550
[TBL] [Abstract][Full Text] [Related]
56. Inflammatory tales of liver cancer.
Hoffmann A; Xia Y; Verma IM
Cancer Cell; 2007 Feb; 11(2):99-101. PubMed ID: 17292819
[TBL] [Abstract][Full Text] [Related]
57. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.
Bettermann K; Vucur M; Haybaeck J; Koppe C; Janssen J; Heymann F; Weber A; Weiskirchen R; Liedtke C; Gassler N; Müller M; de Vos R; Wolf MJ; Boege Y; Seleznik GM; Zeller N; Erny D; Fuchs T; Zoller S; Cairo S; Buendia MA; Prinz M; Akira S; Tacke F; Heikenwalder M; Trautwein C; Luedde T
Cancer Cell; 2010 May; 17(5):481-96. PubMed ID: 20478530
[TBL] [Abstract][Full Text] [Related]
58. Hepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure.
Ehlken H; Kondylis V; Heinrichsdorff J; Ochoa-Callejero L; Roskams T; Pasparakis M
PLoS One; 2011; 6(10):e25942. PubMed ID: 22022477
[TBL] [Abstract][Full Text] [Related]
59. Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis.
Kumari S; Redouane Y; Lopez-Mosqueda J; Shiraishi R; Romanowska M; Lutzmayer S; Kuiper J; Martinez C; Dikic I; Pasparakis M; Ikeda F
Elife; 2014 Dec; 3():. PubMed ID: 25443631
[TBL] [Abstract][Full Text] [Related]
60. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome.
Aigelsreiter A; Haybaeck J; Schauer S; Kiesslich T; Bettermann K; Griessbacher A; Stojakovic T; Bauernhofer T; Samonigg H; Kornprat P; Lackner C; Pichler M
Hum Pathol; 2012 Jul; 43(7):1012-9. PubMed ID: 22176836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
